Case review: Merck defeated in BMS patent row

On March 29, 2016, the US District Court for the District of Delaware denied Merck’s motion to dismiss a Bristol-Myers Squibb (BMS) patent under Federal Rule of Civil Procedure 12(b)(6) regarding the patent ineligibility (based on §101) of a method of treating a metastatic melanoma.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

J&J unit's valuable heart pump saved by 'rare' patent defence

1 June 2026 A district jury has handed a J&J unit a clean sweep in its defence against a rival's heart pump patent claims, delivering a win under the seldom-invoked reverse doctrine of equivalents.

Americas

Federal Circuit tosses $59m trade secrets judgment against EOFlow

29 May 2026 A US appeals court has thrown out a jury verdict against a South Korean medical device company, ruling that Insulet waited too long to bring its trade secret misappropriation claim.

Americas

AI, anxiety, and antibodies: The issues dominating life sciences

26 May 2026 Two days of discussions at LSPN North America revealed an industry grappling with narrower patent claims, global strategy changes, AI disruption and tougher dealmaking conditions.

More features

UPC dispute resolution forum opens with ceremony in Slovenia

J&J unit's valuable heart pump saved by 'rare' patent defence

Federal Circuit tosses $59m trade secrets judgment against EOFlow

Neal Gerber Eisenberg expands in Chicago with new litigator

European court backs AstraZeneca unit in blood cancer combo dispute

Takeda’s China IP head: What pharma is still getting wrong

Boehringer Ingelheim adds ex-Teva executive to patent team

AI, anxiety, and antibodies: The issues dominating life sciences

Case review: Merck defeated in BMS patent row

More on this story

Editor's picks

Editor's picks

More features